Fredun Pharma bonus issue: 2:1, Q4 FY26 profit up 56%

Stock jumps after bonus and results

Shares of Fredun Pharmaceuticals Limited rose around 3% on Tuesday, May 26, after the company announced a 2:1 bonus issue along with strong audited results for the quarter and year ended March 2026. The stock moved as much as 2.7% intraday to a day’s high of ₹2,450 per share on the BSE. The announcement combined a shareholder-friendly corporate action with a sharp improvement in profitability.

The company said the momentum was supported by healthy demand across segments. For investors, the combination of higher earnings and a bonus issue often signals confidence from the board and management in the business trajectory. The key next step is shareholder approval for the bonus issue.

What the board approved on May 25

Fredun Pharmaceuticals said its board meeting on May 25, 2026 approved the audited Q4 and FY26 financial results. At the same meeting, the board recommended a bonus issue in the ratio of 2:1. This means existing eligible holders will receive additional shares without paying anything, subject to the required approvals.

The company communicated the decision through a press release. The proposal covers both shareholders and warrant holders who are eligible as on the record date. The record date itself was not specified in the provided details.

Bonus issue structure: 2:1 explained

Under the proposal, shareholders and warrant holders will receive two fully paid-up equity shares for every one existing fully paid-up equity share held on the record date. The face value of each equity share is ₹10. The company clarified that the bonus issue is subject to shareholder approval.

“The Board of Directors, at its meeting held on May 25, 2026, wherein the audited financial results for Q4 and FY26 were approved, has recommended the issuance of bonus shares in the ratio of 2:1, i.e. 2 fully paid-up equity shares of ₹10 each for every 1 existing equity share of ₹10 each, to eligible shareholders and warrant holders as on the record date, subject to shareholder approval,” the company said in its press release.

A 2:1 bonus issue increases the number of shares held by an investor, while the overall value depends on post-bonus price adjustments and market perception. The corporate action does not change underlying business performance, but it can improve liquidity and broaden participation.

Dividend declared alongside the bonus

Apart from the bonus issue, Fredun Pharmaceuticals also declared a dividend of ₹0.70 per share for shareholders. The update adds to the set of shareholder returns announced with the results.

The company did not provide additional details in the supplied text on dividend record date or payment timeline. Investors typically track these dates closely to understand eligibility.

Q4 FY26 performance: profit growth outpaces revenue

For the March 2026 quarter, Fredun Pharmaceuticals reported a 56% year-on-year rise in net profit to ₹11 crore. The company attributed the performance to robust demand across various segments. The profit growth was significantly ahead of topline growth, indicating improved operating leverage during the quarter.

Revenue for the quarter increased 27% year-on-year to ₹213 crore. EBITDA jumped 67% to ₹29 crore, showing sharper expansion at the operating profit level. The company also highlighted that profitability grew faster than revenue, which it described as an indication of improving business quality.

FY26 snapshot: higher income and margin expansion

For the full financial year FY26, Fredun Pharmaceuticals reported a 60% year-on-year surge in net profit to ₹33 crore. Income rose 40% to ₹639 crore, suggesting broad-based growth through the year.

EBITDA climbed 72% to nearly ₹95 crore. The company reported an EBITDA margin of 14.8% for FY26, pointing to margin expansion compared with the earlier period, although the prior-year margin was not provided in the supplied text. The FY26 figures show that operating profit grew faster than income, consistent with the Q4 trend.

What stood out in the numbers

The key takeaway from the reported results is the pace of profitability improvement relative to revenue growth. In Q4 FY26, EBITDA rose 67% versus revenue growth of 27%, while net profit rose 56%. For FY26, EBITDA growth of 72% outpaced income growth of 40%, and net profit rose 60%.

This pattern generally reflects a mix of better cost control, stronger product mix, pricing, or scale benefits. The company itself described the quarter-end position as a “strong operational footing,” with operating leverage supporting faster profit growth.

Market reaction and what investors tracked

The stock’s rise of around 3% on May 26 followed the combined trigger of the bonus proposal and the audited results. In the session, it rose as much as 2.7% to ₹2,450 per share on the BSE. Such moves often reflect both immediate sentiment and expectations around liquidity and participation after a bonus issue.

Still, the bonus issue remains subject to shareholder approval. Investors will also look for the company’s communication on the record date and the timeline for credit of bonus shares and dividend processing.

Key facts at a glance

What to watch next

The immediate next milestone for the bonus issue is shareholder approval, as stated by the company. After approval, the company is expected to communicate the record date and the corporate action timetable through formal exchange filings.

For investors tracking operations, the focus will remain on whether the pace of margin improvement seen in FY26 and Q4 FY26 sustains. The FY26 margin expansion, combined with strong growth in income and profits, sets a clear benchmark for subsequent quarters.

Conclusion

Fredun Pharmaceuticals’ announcement of a 2:1 bonus issue, along with a ₹0.70 per share dividend and stronger Q4 and FY26 earnings, drove the stock up around 3% on May 26. The company reported Q4 FY26 net profit of ₹11 crore on revenue of ₹213 crore, and FY26 net profit of ₹33 crore on income of ₹639 crore, alongside an FY26 EBITDA margin of 14.8%. The next confirmed step is shareholder approval for the bonus issue, after which the record date and schedule are expected to be communicated.